Use of proton pump inhibitors in adults in France: a nationwide drug utilization study.
Fiche publication
Date publication
décembre 2019
Journal
European journal of clinical pharmacology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BARDOU Marc
Tous les auteurs :
Lassalle M, Le Tri T, Bardou M, Biour M, Kirchgesner J, Rouby F, Dumarcet N, Zureik M, Dray-Spira R
Lien Pubmed
Résumé
Proton pump inhibitor (PPI) drugs are approved for the management of gastric acid-related diseases, mainly treatment of gastroesophageal reflux disease, treatment of nonsteroidal anti-inflammatory drugs (NSAID)-related gastrointestinal complications and prevention in at-risk patients, Helicobacter pylori eradication, and treatment of ulcers. PPIs are one of the most commonly prescribed drug class worldwide, and off-label use is widespread. The aim of this study was to describe outpatient PPI use of the whole adult population in France, based on the French National Health Data System (SNDS).
Mots clés
Acid-related diseases, Drug use, Nationwide, Pharmacoepidemiology, Proton pump inhibitors
Référence
Eur. J. Clin. Pharmacol.. 2019 Dec 14;: